Aurora Cannabis Inc.(ACB)Earnings, Financials & Key Ratios
ACB•NASDAQ
$2.67
Price updated Jul 7, 2026
SectorHealthcareIndustrySpecialty & Generic PharmaSub-IndustryCannabis and cannabinoid product companies
AboutAurora Cannabis Inc. produces, distributes, and sells cannabis and cannabis derivative products in Canada and internationally. It also engages in facility engineering and design, cannabis breeding, research, production, derivatives, product development, wholesale, and retail distribution activities. The company produces various strains of dried cannabis, cannabis oil and capsules, and topical kits for medical patients. It also sells vaporizers; consumable vaporizer accessories; and herb mills for using CanniMed herbal cannabis products, as well as grinders and vaporizer lockable containers. In addition, the company engages in the development of medical cannabis products at various stages of development, including oral, topical, edible, and inhalable products; and operation of CanvasRX, a network of cannabis counseling and outreach centers. Further, it provides patient counselling services; design and construction services; and cannabis analytical product testing services. The company's brand portfolio includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.Show more
- Revenue$321M-6.4%
- EBITDA-$149M-641.9%
- Net Income-$122M-7772.8%
- EPS (Diluted)-2.15-7643.9%
- Gross Margin5.21%-90.5%
- EBITDA Margin-46.35%-678.7%
- Operating Margin-50.78%-3623.1%
- Net Margin-37.98%-8294.1%
- ROE-21.83%-8389.0%
ACB Price & Volume
Aurora Cannabis Inc. (ACB) stock price & volume — 10-year historical chart
Loading chart...
Persistent Revenue Contraction Challenges Operational Sustainability
Investment Thesis • Updated 2026Q4
VerdictNegative
Growth:Decelerating
Profitability:Strained
Financial:Vulnerable
Cash Flow:Deteriorating
Primary Risk:Persistent Revenue Contraction Risk
Key Thesis Takeaways
- Aurora Cannabis faces a precarious outlook characterized by a 57.9% year-over-year revenue decline in 2026Q4 and a massive accumulated deficit of $6.5 billion.
- The company's inability to achieve consistent operating leverage, evidenced by SG&A expenses of $41.5 million exceeding gross profit in the most recent quarter, suggests significant structural headwinds.
- Investors should remain cautious as the firm continues to navigate volatile margins and a thinning liquidity buffer, with cash reserves falling to $112.8 million.
Verdict Logic
the company's inability to generate consistent profitability, highlighted by a net loss of $57.0 million in 2026Q4, suggests that the current operational model remains fundamentally unsustainable.
ACB Growth Metrics
Aurora Cannabis Inc. (ACB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years71.75%
5 Years5.56%
3 Years12.82%
TTM-9.45%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-4815.84%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-4556.4%
Return on Capital
10 Years-12.37%
5 Years-15.14%
3 Years-10.53%
Last Year-25.64%
ACB Recent Earnings
Aurora Cannabis Inc. (ACB) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 5/12 qtrs (42%)
Q3 2026Latest
Jun 11, 2026Metric
Actual
Est
EPS
$0.07+200.0%
$0.07
Rev
$61M+12.0%
$54M
Q1 2026
Feb 4, 2026Metric
Actual
Est
EPS
$0.09-7.4%
$0.10
Rev
$69M+2.0%
$67M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.09+200.0%
$0.03
Rev
$63M-28.4%
$88M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.19-205.6%
$0.18
Rev
$65M-30.9%
$94M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q3 2026Latest | Jun 11, 2026 | $0.07vs $0.07+200.0% | $61Mvs $54M+12.0% |
| Q1 2026 | Feb 4, 2026 | $0.09vs $0.10-7.4% | $69Mvs $67M+2.0% |
| Q4 2025 | Nov 5, 2025 | $0.09vs $0.03+200.0% | $63Mvs $88M-28.4% |
| Q3 2025 | Aug 6, 2025 | $0.19vs $0.18-205.6% | $65Mvs $94M-30.9% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Aurora Cannabis Inc. (ACB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.67 | $165.39M | -1.77 | -6.37% | -37.98% | -21.83% | — | |
| $0.95 | $365.74M | -1.53 | 5.8% | -91.63% | -38.64% | — | |
| $4.31 | $502.21M | -0.13 | 4.84% | -252.55% | -136.55% | — | |
| $2.75 | $1.03B | -112.24 | 64.4% | -0.98% | -0.18% | — | |
| $0.97 | $136.23M | -9.82 | 16.42% | -9.7% | -6.76% | — | |
| $66.79 | $3.89B | 27.04 | -3.93% | 3.27% | — | — |
Compare ACB vs Peers
Aurora Cannabis Inc. (ACB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when ACB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ACB Frequently Asked Questions
Aurora Cannabis Inc. (ACB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Aurora Cannabis Inc.'s revenue?
Aurora Cannabis Inc. (ACB) reported $310.9M in revenue for fiscal year 2026.
How fast is Aurora Cannabis Inc. growing?
Aurora Cannabis Inc. (ACB) saw revenue decline by 6.4% over the past year.
Is ACB profitable?
Aurora Cannabis Inc. (ACB) reported a net loss of $75.0M for fiscal year 2026.
Dividend & Returns
What is ACB's return on equity?
Aurora Cannabis Inc. (ACB) has a return on equity (ROE) of -21.8%. Negative ROE indicates the company is unprofitable.
What is Aurora Cannabis Inc.'s free cash flow?
Aurora Cannabis Inc. (ACB) had negative free cash flow of $36.1M in fiscal year 2026, likely due to heavy capital investments.